Insilico Medicine
🔥 HOTA deep look at Insilico Medicine's finances, team, and market position in the AI Healthcare space.
Awaira Score
Out of 100
HQ
United States
Founded
2014
Raised
$500M
Stage
Public
Team
350
About Insilico Medicine
Insilico Medicine is an AI-driven drug discovery and development company founded in 2014 and headquartered in the USA. The company applies artificial intelligence, machine learning, and generative models to accelerate the identification and optimization of drug candidates across multiple therapeutic areas. Its core platform integrates physics-based modeling with deep learning to predict molecular…
Key Facts
- Insilico Medicine is valued at $1.2B as of March 2026.
- Insilico Medicine has raised a total of $500M in disclosed funding across 3 funding rounds.
- Insilico Medicine was founded in 2014 by Alex Zhavoronkov and is headquartered in United States.
- Insilico Medicine employs approximately 350 people.
- Insilico Medicine operates in the AI Healthcare category and is currently at the Public stage.
- Insilico Medicine has an Awaira Score of 67/100, ranking it among the tracked AI companies on Awaira.
- Insilico Medicine's most recent funding round was a Series C of $37M closed in January 2019.
Source: Awaira · Updated Mar 24, 2026
Valuation
$1.2B
Post-money
Total Raised
$500M
All rounds
Awaira Score
67/100
Founded
2014
350 employees
Strengths & Risks
Strengths
Unicorn status with $1.2B valuation
Strong Awaira Score of 67/100
Growing team of 350 employees
Analysis based on publicly available data. Not investment advice.
Funding Velocity
3
Total Rounds
$18.65M
Avg Round Size
5.1yr
Funding Span
Insilico Medicine raised 3 rounds over 5.1 years, averaging $18.65M per round — a pace of roughly one round every 20 months.
Awaira estimate based on public data. Not financial advice.
How does Insilico Medicine stack up against competitors?
Competitor Comparison
| Metric | ★Insilico Medicine | Butterfly Network | Tempus | Alan |
|---|---|---|---|---|
| Awaira Score | 67/100 | 85/100 | 84/100 | 83/100 |
| Total Raised | $500M | $370M | $1.05B | $750M |
| Valuation | $1.2B | $957M | $8.1B | $5.83B |
| Stage | Public | Public | Public | Series D |
| Founded | 2014 | 2011 | 2015 | 2016 |
| Employees | 350 | 500-1000 | 2500 | 500-1000 |
| Country | 🇺🇸 | 🇺🇸 | 🇺🇸 | 🇫🇷 |
Investors in Insilico Medicine
Funding Rounds
InactiveIllumina Ventures, Lilly Asia Ventures
$37M
Jan 2019
Undisclosed
Jan 2017
$300K
Jan 2014
Insilico Medicine Latest News
Flagship Pioneering Backs Insilico Medicine's AI-First Pharma Approach
Insilico Medicine's AI-Discovered Drug Enters Phase 2 Clinical Trials
Insilico Medicine Announces Strategic Partnerships to Scale AI Operations
Insilico Medicine Secures New Funding to Accelerate Public Expansion
Open Positions at Insilico Medicine
View all jobs →Founded Same Year (2014)
Similar by Funding Stage (Public)
More from United States
🇺🇸 View all AI companies in United States →Alternatives
View all alternatives to Insilico Medicine →If you're looking at Insilico Medicine, also check out
View all AI Healthcare →People Also Viewed
Frequently Asked Questions
What is Insilico Medicine's valuation?▾
Who invested in Insilico Medicine?▾
When did Insilico Medicine last raise funding?▾
How many employees does Insilico Medicine have?▾
What does Insilico Medicine do?▾
Who founded Insilico Medicine?▾
Is Insilico Medicine profitable?▾
Where is Insilico Medicine headquartered?▾
Compare Insilico Medicine
See how Insilico Medicine stacks up against competitors in valuation, funding, team size, and Awaira Score.